Retrospective Dataset of MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) and MD Anderson Dysphagia Index (MDADI) Toxicity Outcomes for Patients Receiving Trans-Oral Robotic Surgery and/or [Chemo]Radiotherapy for Low- to Intermediate-Risk Oropharyngeal Cancer.

Fully anonymized data from 2 publications is presented: <br> 1-Hutcheson KA, Warneke CL, Yao CMKL, Zaveri J, Elgohari BE, Goepfert R, Hessel AC, Kupferman ME, Lai SY, Fuller CD, Gunn GB, Garden AS, Johnson F, Ferrarotto R, Lewin JS, Gross ND; MD Anderson Head and Neck Cancer Symptom Working Group. Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2019 Nov 1;145(11):1053-1063. doi: 10.1001/jamaoto.2019.2725. PMID: 31556933; PMCID: PMC6763976. <br> 2-Hemmati M, Barbon C, Mohamed,ASR van Dijk LV, Moreno, AC Gross ND, Goepfort RP, Lai SY, Hutcheson KA, Schaefer A, Fuller CD, for the MD Anderson Head and Neck Cancer Symptom Working Group. Optimized decision support for selection of transoral robotic surgery or (chemo)radiation: Quantified pre-therapy risk stratification for patient-reported and clinician-graded swallowing impairment and toxicity. medRxiv 2021.06.12.21258794; doi: https://doi.org/10.1101/2021.06.12.21258794 <br> Cohort Description from [1]: "This case series study was a secondary analysis of prospective registry data from 257 patients enrolled from March 1, 2015, to February 28, 2018, at a single academic institution who, according to the AJCC Staging Manual, 7th edition TNM classification, had low- to intermediate-risk human papillomavirus-related oropharyngeal squamous cell carcinoma possibly resectable by trans-oral robotic surgety (TORS). Patients were stratified by primary treatment (75 underwent TORS and 182 received radiotherapy). Modified barium swallow (MBS) studies graded per Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) and the MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN) questionnaires were administered at standard intervals." <br> The enclosed data sheets include anaonymized case data showing average MDASI and composite MDADI scores for baseline (pre-therapy), 3-6 month surveillance interval, and 18-24 months post-therapy; one sheet contains case-level data, while the other represents group summary data by therapy cohort by modality of therapy delivered ("CRT"= Definitive chemoradiotherapy; "RTonly"= Definitive radiotherapy; "TORS + CRT"= Priamry TORS followed by adjuvant chemoradiotherapy; "TORS+RT" =Priamry TORS followed by adjuvant radiotherapy; "TORSonly"= Definitive TORS. <br> Deatials on the scoring of the MDASI-HN are described herein: https://doi.org/10.1016/j.ijrobp.2008.02.072 <br> Specifics of MDADI scoring are described in: https://doi.org/10.1002/lary.25778 and doi:10-1001/pubs.Arch Otolaryngol. Head Neck Surg.-ISSN-0886-4470-127-7-ooa00162. <br> <br> <br> <br> <br>